In this section
Clinical trials
- Participate in a clinical trial
- For medical professionals
- Active clinical trials for pediatric cancers
- CAR-20/19-T cells in pediatric and young adult patients with relapsed/refractory B Cell Acute Lymphoblastic Leukemia (CAR-20/19-T) phase 1 clinical trial
- Unrelated and partially matched related donor peripheral stem cell transplantation for patients with hematologic malignancies clinical trial
- Early stage research
Active clinical trials
Cancer Clinical Trials - PTCTC-ONC1701-ENDRAD
Protocol Summary
- Protocol No
- PTCTC-ONC1701-ENDRAD
- Principal Investigator
- Rachel Phelan
- Phase
- II
- Title
- A Phase II Pilot Trial to Estimate Survival After a Non-Total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed with B-Acute Lymphoblastic Leukemia (ALL) Who Are Pre-Allogeneic Hematopoietic Cell Transplantation (HCT) Next-Generation-Sequence (NGS) Minimal Residual Disease (MRD) Negative
- Associated Disease(s)
-
Acute Lymphoblastic Leukemia (ALL)
- Description (Summary)
- The purpose of this project is to evaluate whether or not patients with NGS-MRD negative result before transplant will have the same or similar medical outcome if they do not receive total body irradiation (TBI) before transplant. In an earlier research study of B-ALL patients receiving transplant, there was a very high survival for NGS-MRD negative patients. All of these patients received conditioning treatment (chemotherapy), with or without total body irradiation (TBI), prior to receiving their transplant.
Historically, patients with B-ALL receive TBI prior to their transplant. TBI can be associated with many negative impacts on long-term growth and cognitive function in children and young adults. Some of these side effects from TBI are more common than what has been reported with chemotherapy treatments. If you are on the Non-TBI Arm of this study, you will receive chemotherapy conditioning treatment without TBI.
- Participating Institutions
- Childrens Hospital of Wisconsin
- ClinicalTrials.gov
Contact us
For more information about cancer and blood disorders clinical trials, email us or call
(414) 955-4727
Get a second opinion
It's important to know what your options are. We can provide expert opinions to verify or give more information about an initial diagnosis. Contact us today.
Why participate in clinical trials?
